Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
It develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.
The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy.
Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -1.31 Increased by +2.24% | -1.06 Decreased by -23.58% |
| May 8, 24 | -1.33 Increased by +3.62% | -1.14 Decreased by -16.67% |
| Feb 27, 24 | -1.38 Increased by +4.83% | -0.97 Decreased by -42.27% |
| Nov 2, 23 | -1.35 Increased by +11.18% | -0.74 Decreased by -82.43% |
| Aug 3, 23 | -1.34 Decreased by -482.61% | -1.15 Decreased by -16.52% |
| May 4, 23 | -1.38 Decreased by -35.29% | -1.20 Decreased by -15.00% |
| Mar 1, 23 | -1.45 Decreased by -302.78% | -1.21 Decreased by -19.83% |
| Nov 3, 22 | -1.52 Decreased by -60.00% | -1.17 Decreased by -29.91% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 463.00 K Increased by +22.49% | -160.54 M Decreased by -24.05% | Decreased by -34.67 K% Decreased by -1.27% |
| Jun 30, 24 | 249.00 K Decreased by -71.28% | -143.32 M Decreased by -11.41% | Decreased by -57.56 K% Decreased by -287.93% |
| Mar 31, 24 | 835.00 K Decreased by -81.90% | -135.64 M Decreased by -4.79% | Decreased by -16.24 K% Decreased by -478.93% |
| Dec 31, 23 | 1.67 M Decreased by -14.56% | -136.90 M Decreased by -4.13% | Decreased by -8.19 K% Decreased by -21.88% |
| Sep 30, 23 | 378.00 K Decreased by -84.97% | -129.42 M Increased by +26.54% | Decreased by -34.24 K% Decreased by -388.77% |
| Jun 30, 23 | 867.00 K Decreased by -99.03% | -128.64 M Decreased by -347.18% | Decreased by -14.84 K% Decreased by -45.79 K% |
| Mar 31, 23 | 4.61 M Increased by +301.83% | -129.44 M Decreased by -28.12% | Decreased by -2.81 K% Increased by +68.12% |
| Dec 31, 22 | 1.96 M Decreased by -96.48% | -131.46 M Decreased by -330.03% | Decreased by -6.72 K% Decreased by -12.12 K% |